AMEX:SENS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe.


Snowflake Analysis

Limited growth with weak fundamentals.


Similar Companies

Share Price & News

How has Senseonics Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SENS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

10.9%

SENS

-1.5%

US Medical Equipment

-0.7%

US Market


1 Year Return

-74.7%

SENS

5.9%

US Medical Equipment

5.3%

US Market

Return vs Industry: SENS underperformed the US Medical Equipment industry which returned 6.9% over the past year.

Return vs Market: SENS underperformed the US Market which returned 6.7% over the past year.


Shareholder returns

SENSIndustryMarket
7 Day10.9%-1.5%-0.7%
30 Day3.7%3.7%4.6%
90 Day-37.5%7.0%14.0%
1 Year-74.7%-74.7%6.8%5.9%7.6%5.3%
3 Year-79.8%-79.8%53.7%49.5%34.9%26.1%
5 Yearn/a99.8%84.2%62.3%44.7%

Price Volatility Vs. Market

How volatile is Senseonics Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Senseonics Holdings undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Senseonics Holdings is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Senseonics Holdings has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of SENS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Senseonics Holdings regulatory filings.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Senseonics Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

9.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SENS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SENS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SENS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SENS's revenue (56.3% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: SENS's revenue (56.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SENS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Senseonics Holdings performed over the past 5 years?

-31.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SENS is currently unprofitable.

Growing Profit Margin: SENS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SENS is unprofitable, and losses have increased over the past 5 years at a rate of -31.4% per year.

Accelerating Growth: Unable to compare SENS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SENS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.4%).


Return on Equity

High ROE: SENS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Senseonics Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: SENS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: SENS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: SENS has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: SENS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SENS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SENS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 37.5% each year


Next Steps

Dividend

What is Senseonics Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SENS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SENS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SENS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SENS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SENS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Tim Goodnow (58yo)

4.58yrs

Tenure

US$2,211,200

Compensation

Dr. Timothy T. Goodnow, also known as Tim, Ph.D., has been the Chief Executive Officer, President and Director of Senseonics Holdings, Inc. since December 2015. Dr. Goodnow served as the Chief Executive Of ...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD2.21M) is above average for companies of similar size in the US market ($USD612.38K).

Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Timothy Goodnow
President4.58yrsUS$2.21m0.19% $185.8k
Mukul Jain
Chief Operating Officer3.5yrsUS$1.40m0.0013% $1.3k
Francine Kaufman
Chief Medical Officer & Director0.67yrUS$1.72m0.070% $68.2k
Nick Tressler
CFO, Secretary & Treasurer0.67yrno datano data

2.4yrs

Average Tenure

52.5yo

Average Age

Experienced Management: SENS's management team is considered experienced (2.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Timothy Goodnow
President4.58yrsUS$2.21m0.19% $185.8k
Francine Kaufman
Chief Medical Officer & Director0.67yrUS$1.72m0.070% $68.2k
Douglas Roeder
Independent Non-Management Director4.58yrsUS$160.60kno data
Edward Fiorentino
Independent Non-Management Director4.58yrsUS$157.50k0.052% $50.3k
Stephen DeFalco
Independent Chairman4.58yrsUS$181.63k0.38% $369.8k
Michael Helmus
Member of Scientific Advisory Boardno datano datano data
Steven Edelman
Independent Non-Management Director3.83yrsUS$154.00k0.048% $46.1k
Douglas Prince
Independent Non-Management Director4.58yrsUS$166.75k0.029% $27.6k
Peter Klein
Independent Non-Management Director4.58yrsUS$157.50k0.031% $29.9k
James Anderson
Member of Scientific Advisory Boardno datano datano data
Michael Pishko
Member of Scientific Advisory Boardno datano datano data

4.6yrs

Average Tenure

62.5yo

Average Age

Experienced Board: SENS's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.6%.


Top Shareholders

Company Information

Senseonics Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Senseonics Holdings, Inc.
  • Ticker: SENS
  • Exchange: AMEX
  • Founded: 1996
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$96.793m
  • Shares outstanding: 227.64m
  • Website: https://www.senseonics.com

Number of Employees


Location

  • Senseonics Holdings, Inc.
  • 20451 Seneca Meadows Parkway
  • Germantown
  • Maryland
  • 20876
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SENSAMEX (NYSE MKT LLC)YesNew Common StockUSUSDDec 2015
6L6DB (Deutsche Boerse AG)YesNew Common StockDEEURDec 2015

Biography

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes for a period of up to 90 and 180 days. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/14 00:01
End of Day Share Price2020/07/13 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.